Ultragenyx Pharmaceutical Profit Margin

The latest profit margin for RARE is -81.79% as of June 2026. That compares with -87.34% in the prior-year period — up 6.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Ultragenyx Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, RARE's profit margin moved from -87.34% to -81.79% — a 6.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ultragenyx Pharmaceutical's valuation or profitability profile.

Against Healthcare companies, RARE currently prints -81.79% for profit margin, while the sector average sits near 13.89%. That is roughly 689.1% below the sector mean. Large gaps often invite a closer look at Ultragenyx Pharmaceutical's growth, margins, and balance sheet.

Profit Margin shows how effectively Ultragenyx Pharmaceutical converts resources into returns. At -81.79%, RARE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -87.34% in the prior-year period — up 6.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RARE's profit margin (-81.79%), review year-over-year change from -87.34%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.